<DOC>
	<DOCNO>NCT02710708</DOCNO>
	<brief_summary>The primary objective ass safety profile YAZ Chinese woman , include adverse drug reaction ( ADRs ) . The secondary objective investigate rate unintended pregnancy , cycle control subject without precede abortion , bleed pattern subject without precede abortion ( include abortion-related bleeding pattern ) efficacy moderate acne vulgaris . Another objective investigate effect dysmenorrhea .</brief_summary>
	<brief_title>YAZ Post Authorization Safety Study ( PASS ) /Post Authorization Efficacy Study ( PAES ) China</brief_title>
	<detailed_description />
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<criteria>Signed date informed consent Chinese female subject request oral contraception , include subject underwent abortion ( medical surgical ) Planned use combine oral contraceptive least 6 cycle Age : 18 45 year ( inclusive ) ; smoker must older 35 year time inform consent At least 4 week postpartum woman breastfeed second trimester abortion Evidence suspicion incomplete abortion ( medical abortion subject must complete abortion confirm ultrasound [ endometrial thickness ≤ 15 mm ] ) . Pregnancy lactation Menstrual disorder consistent ovarian failure ( eg , oligomenorrhea , amenorrhea , hypomenorrhea ) Abuse alcohol , drug , medicine ( eg , laxative ) Inability cooperate study procedure reason ( eg , language comprehension , psychiatric illness , inability get study site ) . Any disease condition compromise function body system could result altered absorption , excessive accumulation , impaired metabolism , alter excretion study medication Any diseases condition might interfere conduct study interpretation result Any contraindication YAZ accord Chinese label , : Renal impairment Adrenal insufficiency A high risk arterial venous thromboembolic disease . Examples include subject know : Have deep vein thrombosis pulmonary embolism , past Have cerebrovascular disease Have coronary artery disease Have thrombogenic valvular thrombogenic rhythm disease heart ( eg , subacute bacterial endocarditis valvular disease , atrial fibrillation ) Have inherit acquire hypercoagulopathies Have uncontrolled hypertension Have diabetes mellitus vascular disease Have headaches focal neurological symptom migraine headache without aura age 35 Breast cancer estrogen progestinsensitive cancer , past Liver tumor , benign malignant , liver disease Hypersensitivity ingredient study drug Undiagnosed abnormal genital bleed Sterilized subject concomitant use hormonal contraception , intrauterine device ( IUD ) , intrauterine system ( IUS ) study For subject qualify moderate acne subgroup : Subjects acne atopy , comedonal acne acne conglobata , sandpaper acne acne multiple large node , cyst , fistular comedo , abscessing fistular duct Use preparation acneinducing effect ( eg , iodinate bromate drug , tuberculostatics , lithium , vitamin B1 [ &gt; 1.5 mg daily ] , B6 [ &gt; 2 mg daily ] , B12 [ &gt; 6 µg daily ] , corticoid , adrenocorticotropic hormone anabolics , quinine , disulfiram , methoxypsoralene , phenobarbital , phenytoin , trimethadione , thyroid depressant , certain oily cosmetic ) Subjects undergoing systemic acne treatment</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>birth control ,</keyword>
	<keyword>contraceptive safety ,</keyword>
	<keyword>contraceptive efficacy ,</keyword>
	<keyword>moderate acne vulgaris</keyword>
</DOC>